Table 1.
Pts | Age | Sex | PRS | FND | Aneurysm location | Size (max, mm) | Treatment | Event | Clinical FU (months) | Radiographic FU (months) | ADR |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 23 | F | SAH | LHO | RP2 | 10.5 | Stent and GDC, later PAO | Thrombus* | 11 | 3 | New sac required PAO |
2 | 48 | F | SAH | NONE | RP2 | 5.5 | Stent and GDC | None | 43 | 43 | None |
3 | 5 | F | SAH | NONE | LP2/P3 | 28 | PAO, GDC | None | 19 | 19 | None |
4 | 45 | F | SAH | RHP | LP2 | 12.5 | PAO, GDC | None | 20 | 13 | None |
5 | 62 | M | IS | LHO | LP2 | 14 | GDC | None | 21 | 25 | GDC embo for recanalization |
6 | 25 | M | SAH | RHP | LP3 | 11 | PAO, GDC | None | 10 | – | None |
7 | 54 | F | SAH | NONE | LP2/P3 | 8 | Stent and GDC | None | 11 | 3 | None |
m, male; f, female; PRS, presentation; SAH, subarachnoid hemorrhage; IS, ischemic stroke; LHO, left hemianopia; RHP, right hemiparesis; RP, right PCA; LP, left PCA; GDC, Guglielmi detachable coils; PAO, parent artery occlusion; FU, follow-up; APR, additional procedure required.
*Thrombus resolved after intra-arterial Abciximab without any clinical sequel.